DEA Draws a Real Line Between Kratom Leaf and the Gas-Station Opioid Products Wearing Its Name

Two DEA scheduling actions landed this month, eleven days apart, and most coverage is going to smash them into one story: “kratom crackdown.” It isn’t one story, and the distinction is the entire point.

On July 1, DEA filed notice, with HHS and FDA backing, to temporarily place concentrated 7-hydroxymitragynine — 7-OH — and three synthetic relatives (mitragynine pseudoindoxyl, MGM-15, MGM-16) into Schedule I, the heroin tier. The Federal Register notice sets a potency threshold — a percentage by dry weight, or roughly a milligram per unit for processed products — below which nothing changes. That threshold is the whole mechanism: it’s built to catch the vape-shop shots and gas-station “extracts” engineered to isolate 7-OH at opioid-strength concentrations, while stepping around the actual kratom leaf, which carries only trace 7-OH naturally. DEA’s own language says as much: the action “does not apply to botanical kratom products that contain naturally occurring 7-OH below the specified threshold.” A mandatory 30-day clock means the order can’t take effect before roughly August 5.

What should end the “is kratom getting banned” confusion outright: the American Kratom Association — the leaf industry’s own trade group — came out in favor of this, saying it “confirms chemically manipulated 7-OH opioid products are not kratom.” An advocacy group does not typically cheer for its own product’s scheduling. It cheers when regulators finally stop conflating its product with the thing that’s been strip-mining its reputation.

The second action is unrelated in substance but not in spirit. On July 8, DEA proposed permanently scheduling tianeptine — an antidepressant approved abroad, sold here as an unregulated supplement, and nicknamed “gas station heroin” because high doses turn it into a full opioid agonist. Comments close August 7. Roughly fifteen states have already banned or scheduled it on their own, which tells you the federal government is closing a gap states were already sprinting to fill, not leading from the front.

I think this is the regulatory posture harm reduction should actually want: precise, threshold-based, aimed at the engineered high-potency product rather than the plant or the person who uses it. It’s the opposite of the reflex that swept mephedrone analogs and then kratom itself into blanket panic bans a decade ago, catching people who took a low dose in the same net as the shot-in-a-can crowd. If you use kratom leaf to manage withdrawal or chronic pain, nothing here touches your legal access — not yet, and not by this action’s design. If you’re buying 7-OH shots or tianeptine off a counter display, that supply is about to get harder to find and riskier to substitute, inside weeks, not years. Plan around that now — don’t wait for the order to publish to find out your source just became a felony.